These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 20538719
1. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats. Greischel A, Binder R, Baierl J. Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719 [Abstract] [Full Text] [Related]
3. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA. Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971 [Abstract] [Full Text] [Related]
4. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619 [Abstract] [Full Text] [Related]
6. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Fuchs H, Binder R, Greischel A. Biopharm Drug Dispos; 2009 Jul; 30(5):229-40. PubMed ID: 19562682 [Abstract] [Full Text] [Related]
9. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ. Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124 [Abstract] [Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Graefe-Mody U, Retlich S, Friedrich C. Clin Pharmacokinet; 2012 Jul 01; 51(7):411-27. PubMed ID: 22568694 [Abstract] [Full Text] [Related]
11. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ. Clin Ther; 2013 Jan 01; 35(1):A33-42. PubMed ID: 23328275 [Abstract] [Full Text] [Related]
15. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial. Friedrich C, Jungnik A, Retlich S, Ring A, Meinicke T. Drug Res (Stuttg); 2014 May 01; 64(5):269-75. PubMed ID: 24154935 [Abstract] [Full Text] [Related]
16. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes. Med Lett Drugs Ther; 2011 Jun 27; 53(1367):49-50. PubMed ID: 21701440 [No Abstract] [Full Text] [Related]
17. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Neumiller JJ. Ann Pharmacother; 2012 Mar 27; 46(3):358-67. PubMed ID: 22318932 [Abstract] [Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Tiwari A. Curr Opin Investig Drugs; 2009 Oct 27; 10(10):1091-104. PubMed ID: 19777398 [Abstract] [Full Text] [Related] Page: [Next] [New Search]